- Company
- SK bioscience collaborates with the Doherty Institute
- by Jun 28, 2023 05:53am
- SK bioscience announced on the 27th that it had signed a research cooperation agreement with the Peter Doherty Institute for Infection and Immunity in Australia for global influenza prevention and response. The Peter Doherty Institute for Infection and Immunity is an infectious disease research institute affiliated with the University of Melb
- Company
- Reimb progress of 2 NMOSD drugs receive attention in 2H
- by Eo, Yun-Ho Jun 28, 2023 05:52am
- Whether the two optic nerve sclerosis drugs that have remained non-reimbursed for a long time in Korea will be reimbursed this time is receiving attention. According to industry sources, discussions are ongoing to introduce the agenda on reimbursing the neuromyelitis optica spectrum disorder (NMOSD) indication of ’Soliris (eculizumab)’
- Company
- B-cell lymphoma drug Polivy applies for reimb again
- by Eo, Yun-Ho Jun 27, 2023 05:47am
- The B-cell lymphoma drug ‘Polivy’ is reattempting to receive reimbursement in Korea. This time, the company applied for Polivy’s reimbursement with a different indication. According to industry sources, Roche Korea submitted an application for the reimbursement of its Diffuse Large B-Cell Lymphoma (DLBCL) treatment Polivy (polatuzumab
- Company
- Boryung Lenvima passed the first hurdle of the patent challe
- by Kim, Jin-Gu Jun 26, 2023 05:53am
- Boryung succeeded in crossing the first hurdle in the patent challenge for Lenvima, a liver cancer treatment. If the remaining two patents are avoided or invalidated, the early generic release is expected to be faster. According to the pharmaceutical industry on the 23rd, the Intellectual Property Trial and Appeals Board sided with Boryeong i
- Company
- Entresto’s reimb for HFrEF is extended again
- by Eo, Yun-Ho Jun 26, 2023 05:53am
- The reimbursement standards for the heart failure treatment ‘Entresto’ has been extended once again. According to industry sources, the reimbursement standards for Entresto (sacubitril) will be revised starting next month (July) to cover its use in combination with
- Company
- Xospata makes progress for reimb...up for DREC review
- by Eo, Yun-Ho Jun 23, 2023 05:45am
- The reimbursement review for the acute myeloid leukemia treatment Xospata is making way to overcome the existing restriction that limits the reimbursement to 4 cycles. According to industry sources, Xospata (gilteritinib), Astellas Korea’s new drug for patients with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutatio
- Company
- IND of LegoChem Bio's ADC was approved by the FDA
- by Hwang, Jin-joon Jun 23, 2023 05:44am
- LegoChem Bioscience announced on the 22nd that it has received approval from the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial plan (IND) for 'LCB84' targeting various solid cancers such as triple-negative breast cancer and colorectal cancer. It submitted a clinical trial protocol to the FDA in May and obtained plan app
- Company
- Expansion of indications for Forxiga as a treatment for HFrE
- by Jung, Sae-Im Jun 23, 2023 05:43am
- AstraZeneca Korea announced on the 22nd that its SGLT-2 inhibitor Forxiga has additionally obtained indications for HFpEF and HFmrEF from the Ministry of Food and Drug Safety. The indication approved this time is to reduce the risk of death due to cardiovascular disease, hospitalization due to heart failure, and urgent hospital visits due to
- Company
- GO for patent litigation, NO for suspension of execution
- by Kim, Jin-Gu Jun 22, 2023 04:14pm
- Janssen Korea has decided not to file a lawsuit for canceling a drug price cut and a request for suspension of execution following the appeal in a patent dispute. It is interpreted as an intention to avoid controversy over the abuse of the suspension system related to the so-called 'Drug Price Reduction and Refund Act' that recently passed the N
- Company
- Leclaza confirms brain metastasis benefits
- by Hwang, byoung-woo Jun 22, 2023 05:41am
- "I think this is a meaningful study in that the third-generation EGFR TKI treatment, such as Lazertinib, showed data related to brain metastasis, but clearly focused on the intracranial response to confirm the effect." When brain metastasis occurs in non-small cell lung cancer patients using 1st or 2nd generation EGFR TKI agents, most patients'
